Pismo Beach, CA, June 1, 2020 – Today MACE Media Group published the latest issue of CBD Health & Wellness Magazine with a cover and feature article devoted to Cannabinoid Industry Association (CBDIA) Board Member Jim DeMesa, MD, MBA, Emerald Health Pharmaceuticals (EHP) President and CEO, and his colleagues.
The issue highlights the development of a novel cannabinoid compound, EHP-101, currently in testing as a treatment for multiple sclerosis (MS). Dr. DeMesa discussed how this new cannabinoid-derived therapy could significantly impact disease course and potentially achieve the “Holy Grail” of MS by reversing the neural damage caused by the disease.
MACE Media Group CEO Celeste Miranda, who lives with MS, introduces the feature article with a heartfelt note about her experience and how cannabinoids have been instrumental in managing her symptoms. Miranda’s commitment to the cannabinoid industry is a personal one and she is honored to share this research.
“CBDIA exists to bring together leaders in the cannabinoid industry to foster collaboration and growth. Through our publications, we seek to highlight the latest findings from industry leaders and medical professionals and are thrilled to share the cutting-edge research of companies like EHP that are working hard to bring new cannabinoid-based therapies to patients,” noted Miranda.
In the article, Dr. DeMesa discusses years of diligent work led by Eduardo Muñoz, MD, PhD and Giovanni Appendino, PhD to modify and optimize cannabinoid molecules and make them better suited to target certain receptors and biologic pathways throughout the body which are targets for various diseases with unmet medical needs. EHP is currently advancing EHP-101 through clinical trials to assess its treatment potential for systemic sclerosis and MS, and is conducting preclinical work on a second molecule, EHP-102, focused on Parkinson’s disease and Huntington’s disease.
“It is an honor to have the opportunity to discuss our work at EHP with the CBDIA community,” said Dr. DeMesa. “Our approach to developing a new treatment paradigm for diseases like MS with unmet medical needs and no cures is based on the convergence of cannabinoids, biology, and science. Our initiation of Phase II is now underway with EHP-101, which is a novel, patented synthetic cannabidiol (CBD) derivative that has demonstrated significant, positive results in pre-clinical and Phase I studies.”
The CBD Health & Wellness team is grateful to Dr. DeMesa’s for sharing his insights with our readers.
About MACE Media Group
MACE Media Group publishes niche cannabis industry trade publications. Its first title, Terpenes and Testing Magazine, was the first industry trade publication devoted to cannabis science. Its newer publications, CBD Health & Wellness Magazine, Extraction Magazine, and TOPICAL Magazine, revolve around the growing CBD and cannabinoid industry to provide news on trending applications, medical research, and updates with laws and regulations.
MACE also produces many trade events that attract dozens of cannabis and mainstream media journalists. Currently, MACE Media Group is producing a tour of CBD expos bringing together thousands of industry influencers, forming the most comprehensive CBD event in the United States.
Find out more at MACE Media Group.
CBDIA empowers professionals in the cannabinoid industry with education, advocacy, and community. We serve as the premier expert resource on trends, technologies, legalities, limitations, developments, and other issues that affect your business by nourishing a community of shared knowledge and resources to benefit everyone. CBDIA elevates awareness and expands knowledge and advocate for legal and regulatory environments that benefit our entire industry.
Find out more at CBDIA.
PURCHASE Your Copy of CBD Health & Wellness Magazine HERE